E3 peptide vaccine: Fukami et al. explored a novel long-term solution to dyslipidemia and atherosclerosis by developing a peptide-based vaccine with epitopes targeting ANGPTL3. This evidence concerns the gene ANGPTL3 and metabolic syndrome.